Study: Once-a-week diabetes drug works better than twice-daily injectionSusannah F. Locke
First, the study had a 26-week duration and sustained effects were not studied. Second, there was the potential for selection bias owing to the number of injections; however, compared with regimens for daily basal insulin, the regimen in this trial only required 1 extra injection per week (...
Once‐weekly Trulicity is a type 2 diabetes medication for adults that helps your body release its own insulin and can help improve your A1C and blood sugar numbers. For adults living with T2DM, Trulicity lowers the risk of CV events like heart attack, s
Hemodialysis was introduced once a week in an elderly patient who could not walk because of left hemiplegia, and who had previously refused hemodialysis. The patient was observed for one year. She was an 82-year-old woman who had trouble as an inpatient because of her egocentric personality....
Patients with type 2 diabetes receiving once-weekly insulin icodec were more likely to reach a hemoglobin A1C level below 7% compared to those who received once-daily insulin analogues.
New indication based on clinical trial that demonstrated a 16.1% reduction in body mass index (BMI) in teens with obesity treated with Wegovy® (semaglutide) injection 2.4 mg compared to placebo (0.6% increase in BMI) 1 Approval represents a step forward in the management of teenage obesity...
- 《Diabetes Research & Clinical Practice》 被引量: 73发表: 2007年 Management of spontaneous diabetes mellitus in a companion rat (Rattus norvegicus) Rats are a common model for diabetes mellitus in humans, but spontaneous diabetes in pet rats has not been described. A 1-year, 5-month-old,...
The Institute of Health Economics Diabetes Cohort Model (IHE-DCM) was used to project life expectancy, quality-adjusted life years (QALYs), and total direct medical cost over 40 years from a Chinese healthcare system perspective. Baseline characteristics, clinical effectiveness, and the treatment do...
This 4-week, phase 3b, multicenter, open-label, single-arm, outpatient study demonstrated the safe and effective use of the dulaglutide single-dose pen containing 0.5 mL of placebo for subcutaneous injection in injection-nave adult patients with type 2 diabetes (T2D), with A1C ≤ 8.5% (69 ...
Administered by once-daily subcuta- neous injection at doses up to 1.8 mg, liraglutide (Victoza) is approved for the treatment of T2DM. Liraglutide 3.0 mg is currently under development for chronic weight management. Results from a phase 2 randomized, placebo-controlled trial of liraglutide (...